4-76161738-T-A
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM2PM5BP4_Moderate
The NM_005506.4(SCARB2):c.1412A>T(p.Glu471Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000137 in 1,461,872 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E471G) has been classified as Uncertain significance.
Frequency
Consequence
NM_005506.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SCARB2 | NM_005506.4 | c.1412A>T | p.Glu471Val | missense_variant | 12/12 | ENST00000264896.8 | |
SCARB2 | NM_001204255.2 | c.983A>T | p.Glu328Val | missense_variant | 9/9 | ||
SCARB2 | XM_047416429.1 | c.938A>T | p.Glu313Val | missense_variant | 12/12 | ||
SCARB2 | XM_047416430.1 | c.938A>T | p.Glu313Val | missense_variant | 12/12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SCARB2 | ENST00000264896.8 | c.1412A>T | p.Glu471Val | missense_variant | 12/12 | 1 | NM_005506.4 | P4 | |
ENST00000651366.1 | n.102+12472T>A | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000399 AC: 10AN: 250596Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135526
GnomAD4 exome AF: 0.0000137 AC: 20AN: 1461872Hom.: 0 Cov.: 30 AF XY: 0.00000825 AC XY: 6AN XY: 727248
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Action myoclonus-renal failure syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 27, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Sep 29, 2022 | PM2 - |
Progressive myoclonic epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 03, 2021 | This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 471 of the SCARB2 protein (p.Glu471Val). This variant is present in population databases (rs755903502, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with SCARB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 582195). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at